Untreated Narcolepsy — Severe Excessive Daytime Sleepiness
Narcolepsy drives dozing in nearly every daily situation, untreated.
- 18-24: Typical untreated Epworth (severe range)
- ~1 in 2,000: Narcolepsy prevalence (US population)
- >90%: Orexin neuron loss (type 1 narcolepsy)
- ~8-10: Years to diagnosis (average delay)
What the Epworth scale measures
Eight everyday situations rated 0-3 for dozing chance.
Why narcolepsy scores so high
Orexin loss destabilizes wake state control severely.
Impact of untreated severe EDS
Driving, work, and safety risks rise sharply.
Treatment Initiated — Starting a Wake-Promoting Agent
A wake-promoting drug is prescribed and titrated to target dose.
- Modafinil, solriamfetol: First-line agents (wake-promoting class)
- Low, titrated: Typical starting dose (up over 1-2 weeks)
- Days: Onset of any effect (full effect later)
- Nighttime dosing: Oxybate option (consolidates sleep)
Wake-promoting drug classes
Modafinil, solriamfetol, and pitolisant target distinct pathways.
Titration and adherence
Consistent daily dosing drives predictable improvement.
Setting expectations
Score reduction builds gradually over weeks, not days.
Weeks 2-4 — Partial Epworth Score Reduction
Dozing likelihood drops first in passive, low-stimulation situations.
- ~5-8 pt drop: Typical score by week 4 (from baseline)
- TV, reading: Situations improving first (passive settings)
- Weeks 1-4: Dose adjustment window (common titration period)
- Large: Adherence effect (missed doses blunt gains)
Early pharmacologic effect
Steady-state drug levels begin stabilizing wakefulness.
Which items improve first
Passive dozing triggers respond before active ones.
Adherence matters most now
Skipped doses noticeably slow early gains.
Weeks 8-12 — Trending Toward the Normal Range
Sustained dosing pushes the total score closer to normal levels.
- ~9-12: Typical score by week 12 (mild-to-normal range)
- Notable: Driving-item improvement (safety-relevant gain)
- ~10-12 wks: Plateau onset (diminishing returns begin)
- ≤10: Normal Epworth cutoff (general population)
Long-term response pattern
Improvement decelerates as it approaches a plateau.
Residual sleepiness
Some patients retain mild residual EDS despite therapy.
Monitoring during this phase
Repeat Epworth scoring tracks ongoing response.
Meaningful, Sustained Reduction in Daytime Sleepiness
A clinically meaningful Epworth drop reflects real functional gains.
- ~2 pts: Minimal clinically important diff. (established threshold)
- ~40-60%: Responders reaching ≤10 (on monotherapy)
- Common: Combination therapy option (for partial responders)
- Every visit: Ongoing reassessment (Epworth re-scored routinely)
Defining treatment response
A drop of 2+ points is considered clinically meaningful.
Partial vs full responders
Some patients need add-on or combination therapy.
Long-term management
Periodic Epworth rescoring guides dose adjustments.